News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Incyte Corporation (INCY) Reports First-Quarter 2013 Financial Results; Updates Shareholders on Key Clinical Programs



5/2/2013 8:14:13 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Incyte Corporation (Nasdaq: INCY) today reported first-quarter 2013 financial results, including revenue from JakafiĀ® (ruxolitinib), which is approved by the U.S. Food & Drug Administration (FDA) for the treatment of patients with intermediate or high-risk myelofibrosis (MF). The Company also updated information about key clinical programs.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES